BioMarin Pharmaceutical Inc.
General ticker "BMRN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $11.6B (TTM average)
BioMarin Pharmaceutical Inc. does not follow the US Stock Market performance with the rate: -10.6%.
Estimated limits based on current volatility of 1.2%: low 55.82$, high 57.17$
Factors to consider:
- Total employees count: 3040 (-10.6%) as of 2024
- Top business risk factors: Strategic risks and growth management, Economic downturns and volatility, Regulatory and compliance, Litigation risks, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [47.94$, 79.64$]
- 2025-12-31 to 2026-12-31 estimated range: [48.71$, 79.94$]
Financial Metrics affecting the BMRN estimates:
- Negative: with PPE of 18.8 at the end of fiscal year the price was high
- Positive: 7.61 < Operating profit margin, % of 16.91
- Negative: -0.18 < Industry inventory ratio change (median), % of 0
- Positive: 1.84 < Return on assets ratio (scaled to [-100,100]) of 5.76
- Negative: Industry earnings per price (median), % of -16.05 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term BMRN quotes
Long-term BMRN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2,096.04MM | $2,419.23MM | $2,863.91MM |
| Operating Expenses | $1,935.07MM | $2,233.45MM | $2,379.70MM |
| Operating Income | $160.97MM | $185.77MM | $484.21MM |
| Non-Operating Income | $-11.40MM | $2.79MM | $57.55MM |
| Interest Expense | $15.97MM | $17.34MM | $12.67MM |
| R&D Expense | $649.61MM | $746.77MM | $747.18MM |
| Income(Loss) | $149.58MM | $188.56MM | $541.76MM |
| Taxes | $8.02MM | $20.92MM | $114.90MM |
| Profit(Loss)* | $141.56MM | $167.65MM | $426.86MM |
| Stockholders Equity | $4,603.16MM | $4,951.55MM | $5,657.99MM |
| Inventory | $894.08MM | $1,107.18MM | $1,232.65MM |
| Assets | $6,375.07MM | $6,841.60MM | $6,988.94MM |
| Operating Cash Flow | $175.90MM | $159.26MM | $572.84MM |
| Capital expenditure | $120.96MM | $96.69MM | $97.42MM |
| Investing Cash Flow | $-20.03MM | $-111.24MM | $136.49MM |
| Financing Cash Flow | $-18.65MM | $-18.73MM | $-526.45MM |
| Earnings Per Share** | $0.76 | $0.89 | $2.25 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.